<DOC>
	<DOCNO>NCT01501370</DOCNO>
	<brief_summary>Histone deacetylase ( HDAC ) inhibitor represent potential new class antitumor agent . Vorinostat ( suberoylanilide Hydroxamic acid , SAHA ) inhibit activity 11 know human class I II HDACs . HDACs many protein target whose structure function alter acetylation , include histone non-histones protein component transcription factor control gene expression protein regulate cell proliferation , migration death ( 1 ) . Vorinostat undergone initial evaluation several phase I II clinical trial solid hematologic malignancy . It show activity hematologic malignancy include Hodgkin 's disease non Hodgkin 's lymphoma ( 2-5 ) ; approve treatment cutaneous manifestation patient primary cutaneous T-cell lymphoma progressive , persistent recurrent disease follow two systemic therapy ( 6 ) . HDAC function critical Multiple Myeloma ( MM ) cell actively maintain transcriptional program indispensable uncontrolled proliferation and/or inappropriate resistance pro-apoptotic stimulus . The pleiotropic anti-MM effect Vorinostat ability sensitize MM cellsto multiple conventional novel agent ( 7 ) provide framework clinical trial Vorinostat MM . A phase I trial oral Vorinostat alone advance MM show modest activity , treatment generally well tolerate ( common drug related adverse event ( AEs ) include fatigue , anorexia , dehydration , diarrhea nausea mostly grade &lt; 2 ) ( 8 ) . A phase I clinical trial Vorinostat association Bortezomib relapse MM patient report partial response ( PR ) rate 42 % , responses occur also patient refractory previous Bortezomib base regimen . Treatment generally well tolerate ( main adverse event myelosuppression , fatigue diarrhea ) ( 9 ) . Lenalidomide active agent MM , show activity relapse newly diagnose setting , combination chemotherapy steroid . The dose Lenalidomide commonly use relapse setting , association steroid , 25 mg/day day 1-21 every 28 day ( 10 , 11 ) . A recent phase I study evaluated safety tolerability Vorinostat combination Lenalidomide Dexamethasone relapse patient : dose limit toxicity prohibit dose escalation , maximum tolerate dose reach maximum administer dose Lenalidomide 25 mg/day day 1-21 , Dexamethasone 40 mg/day day 1,8,15,22 , Vorinostat 400 mg/day day 1-7 15-21 ; cycle repeat every 28 day . Rate least PR 51 % , activity see also patient receive prior Lenalidomide therapy ( clinical benefit report 69 % patient , include minimal response well 33 % Lenalidomide refractory patient ) . The common drug relate grade &gt; 3 AEs neutropenia , thrombocytopenia , diarrhea , anemia fatigue ( 12 ) . Since Vorinostat show efficacy also patient previously treat Lenalidomide , patient refractory Lenalidomide , investigator hypothesis addition Vorinostat low-dose dexamethasone Lenalidomide ( ZLd ) , patient experience biochemical relapse Lenalidomide maintenance ongoing therapy , overcome Lenalidomide-drug resistance result significant response rate , translate significant improvement survival MM patient . The second hypothesis , since dose Lenalidomide commonly administer maintenance therapy , 10 mg day 1-21 every 28 day , increase Lenalidomide dose standard dose use relapse patient , plus low-dose Dexamethasone ( Ld ) , patient experience biochemical relapse Lenalidomide ongoing maintenance , well overcome Lenalidomide-drug resistance determine significant response rate , translate significant improvement survival MM patient . This multicenter non comparative , randomize , open label , phase II study . Patients , receive Lenalidomide maintenance treatment without prednisone , randomize receive : Cohort 1 : ZLd association : Lenalidomide orally dose 25 mg/day 21 day every 28 day Vorinostat orally dose 400 mg/day day 1-7 15- 21 28-day cycle . Dexamethasone orally dose 40 mg day 1,8 , 15 , 22 every 28 day . Cohort 2 : Ld association : Lenalidomide orally dose 25 mg/day 21 day every 28 day Dexamethasone orally dose 40 mg day 1,8 , 15 , 22 every 28 day . Patients must -confirmed diagnosis relapse multiple myeloma . In Phase II study , total 35 patient ZLd cohort 48 Ld cohort enrol . It anticipate full accrual study take approximately 36 month .</brief_summary>
	<brief_title>Vorinostat Plus Lenalidomide Dexamethasone Lenalidomide Plus Dexamethasone Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 year . Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal 24 consecutive month surgically sterilize agree continuous abstinence heterosexual sexual contact willing use effective contraception 4 week prior begin study drug therapy , study drug therapy ( include dose interruption ) 4 week discontinuation therapy ; female patient pregnant nursing ; female negative pregnancy test . Male patient agree use acceptable method contraception study drug therapy ( include dose interruption ) 4 week discontinuation therapy . Patient diagnose MM base standard criterion , measurable disease ( 14,15 ) , define follow : Secretory myeloma : quantifiable serum monoclonal protein value ( generally , necessarily , great 1 g/dL IgG MProtein great 0.5 g/dL IgA MProtein ) , and/or applicable , urine lightchain excretion &gt; 200 mg/24 hour involve free light chain ( FLC ) level &gt; 10 mg/dl provide serum FLC ratio abnormal ; Nonsecretory myeloma : &gt; 30 % plasma cell bone marrow least one plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e. , MRI CT scan ) . Patient receive Lenalidomide maintenance therapy part first line treatment ( concomitant use prednisone accept ) experience biochemical relapse , evidence progressive disease define increase 25 % low response value one following : Serum Mcomponent ( absolute increase must ≥ 0.5 g/100 ml ) and/or Urine Mcomponent ( absolute increase must ≥ 200 mg per 24 h ) ; patient without measurable serum urine Mprotein level : difference involve uninvolved FLC level ( absolute increase must &gt; 10 mg/l ) ( 12 ) . No evidence end organ damage attribute underlying plasma cell proliferative disorder , specifically hypercalcemia ( serum calcium ≥ 11.5 mg/100 ml ) renal insufficiency ( serum creatinine &gt; 1.73 mmol/l ) , anemia ( hemoglobin value &gt; 2 g/100 ml low limit normal hemoglobin value &lt; 10 g/100 ml ) bone lesion ( lytic lesion , severe osteopenia pathologic fracture ) ( 11 ) . Patient Karnofsky performance status ≥ 60 % . Patient lifeexpectancy &gt; 3 month . Patient active infectious hepatitis type B C know HIV infection . Patient congenital long QT syndrome right bundle branch block + leave anterior hemiblock ( bifascicular block ) . Screening ECG QTc &lt; 450 msec . Patient take antiarrhythmic drug medicinal product lead QT prolongation cumulative high dose anthracycline . Patient clinically significant illness would , investigator 's opinion , increase patient 's risk toxicity . Patient currently active malignancy , non melanoma skin cancer carcinoma situ cervix . Patients consider currently active second malignancy complete therapy prior malignancy , disease free prior malignancy &gt; 5 year consider physician less 30 % risk relapse . No history allergic reaction attribute study agent . No prior exposure HDACi . Patients expose valproic acid could eligible wash period least 30 day . More 30 day since prior class Ia , Ib Ic antiarrhythmic medication . Patient follow laboratory value within 28 day baseline day 1 cycle 1 : Platelets count ≥ 75 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) , total bilirubin : ≤ 2 x upper limit normal ( ULN ) . Calculated measured creatinine clearance : ≥ 20 mL/minute PT PTT : ≤ 1.5 ULN Serum potassium ≥ LLN Serum magnesium ≥ LLN Serum phosphorus ≥ LLN Any serious medical condition , laboratory abnormality , psychiatric illness social situation would prevent subject signing informed consent form limit compliance study medication requirement . Pregnant beast feeding female . Use concomitant standard/experimental antimyeloma drug therapy . Known positive HIV active infectious hepatitis , type B C. Known congenital long QT syndrome right bundle branch block + leave anterior hemiblock ( bifascicular block ) . Screening ECG QTc &gt; 450 msec . Ongoing therapy antiarrhythmic drug medicinal product lead QT prolongation cumulative high dose anthracycline . Patient currently active malignancy , non melanoma skin cancer carcinoma situ cervix . Patients consider currently active second malignancy complete therapy prior malignancy , disease free prior malignancy &gt; 5 year consider physician less 30 % risk relapse . History allergic reaction attribute study agent . Prior exposure HDACi . Patients expose valproic acid could eligible wash period least 30 day . Less 30 day since prior class Ia , Ib Ic antiarrhythmic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Biochemical relapse</keyword>
</DOC>